Walmsley runs GSK’s $10 billion consumer healthcare unit, a portfolio of popular OTC brands including Horlicks, Sensodyne and Flonase that now accounts for 26% of the drugmaker’s 2015 sales. The division, formed in 2014 as a joint venture between Novartis and GSK, operates in 160 countries. In 2015, Walmsley continued to lead the integration of the business while getting good results: global sales for the group increased 44%; profits jumped 76%.
Personal Information
| Country | U.K. |
| 2020 Rank | #24 (EMEA) |
| Newcomer? | No |
Company Financials
| 2017 Revenues | $36,550 |
| 2017 Profits | $12,867 |
| Market Value as of 08/30/18 ($M) | $105,168 |